Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Anthony@Pacific who wrote (74800)	1/27/2002 11:25:17 PM
From: oldirtybastard	Read Replies (2) \| Respond to of 122087

Any from the NYSE? -g-

To: Anthony@Pacific who wrote (74800)	1/27/2002 11:58:11 PM
From: Buckey	Respond to of 122087

we should string them all up by the balls and hope that they join our USXP friend. Look up Ron williams here dc.state.fl.us he is the white guy at the top[ of the list

To: Anthony@Pacific who wrote (74800)	1/28/2002 8:25:30 AM
From: The Osprey	Respond to of 122087

ADRX looks like it could suffer woe if this "sell" recommendation becomes widely read.Here are excerpts of the recommendation. Andrx: Is Wall Street Blinded by Love?" In virtually a parallel tale of woe, this drug maker also received glowing reports from the majority of Wall Street analysts who covered the firm. According to the article, "of the 18 analysts who follow the company, a few have qualms about the stock's valuation. Only Sterling is outright negative and has put a rare `sell' rating on the stock." Some of the reasons cited by Sterling include; "near earnings decline, a high relative valuation and a reliance on acquisitions for growth." Sterling concluded by saying, "A past history of insider selling does not help share price strength either. Insiders: biz.yahoo.com Looks like a further short to me as well.What do you think Anthony.May warrant further consideration??? The Osprey